肠道微生物组研究进展:英国胃肠病学会专家组的分析
本文回顾了英国胃肠病学会肠道微生物组健康专家组近十年的研究进展,指出研究已从小样本16S rRNA基因扩增子特征分析转向大规模多中心研究,并越来越多地采用鸟枪法宏基因组学和其他组学技术。粪菌移植已确立用于治疗复发性艰难梭菌感染,其他微生物治疗技术显示前景但尚未达到预期。
要点
- 肠道微生物组研究已从边缘兴趣转变为主要全球研究方向。
- 粪菌移植已确立用于复发性艰难梭菌感染,部分国家已有下一代产品获批。
- 营养、噬菌体和益生菌等微生物治疗技术显示前景但尚未满足高期望。
核心结论
- 肠道微生物组研究已确立并显示显著转化潜力,未来重点将是通过转化工作推动其在临床诊断、预后和治疗中的应用。
研究设计与样本
- 本文为英国胃肠病学会肠道微生物组健康专家组的分析,评估该领域十年进展并承认持续挑战。
主要发现
- 早期小队列中特定条件的16S rRNA基因扩增子特征研究已被具有广泛元数据的大型多中心研究取代。
- 研究越来越多地采用鸟枪法宏基因组学和其他组学技术,结合改进的生物信息学工具和疾病模型。
- 微生物组分析的金标准流程出现和信号机制验证增加是朝向更临床可转化结果的关键进展。
- 肠道微生物组相关的新临床领域出现,包括生命早期和某些治疗(包括免疫检查点抑制剂和疫苗接种)的疗效。
- 粪菌移植已确立用于治疗复发性艰难梭菌感染,供体来源的下一代粪菌移植产品在某些国家获批用于该病症。
临床怎么用
- 粪菌移植可用于治疗复发性艰难梭菌感染。
- 微生物组诊断和治疗 enthusiasm 增长,但广泛采用仍存在障碍。
局限性
- 其他微生物治疗技术(包括营养、噬菌体和益生菌疗法)显示前景但尚未满足高期望。
- 微生物组诊断和治疗的广泛采用仍存在障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At around 10 years ago, at the time of the first publication by the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology, recognition of the gut microbiome's importance in health and disease was transitioning from fringe interest towards major global pursuit. A decade on, we appraise the considerable progress made in the field, while acknowledging ongoing challenges. Earlier human work characterising the 16S rRNA gene amplicon signature of particular conditions in small cohorts has been superseded by larger, multicentre studies with extensive metadata. Studies increasingly employ shotgun metagenomics and other 'omic' techniques-coupled with refined bioinformatic tools and disease models-to better characterise perturbation in gut microbiome functionality. The arrival of 'gold standard' pipelines for microbiome analysis and increased mechanistic validation of signals are key developments towards more clinically-translatable outcomes. Novel clinical areas where the gut microbiome has relevance have emerged, including early life and the efficacy of certain treatments (including immune checkpoint inhibitors and vaccination). Enthusiasm for 'microbiome diagnostics and treatments' has grown, but barriers to widespread adoption remain. Faecal microbiota transplant (FMT) is established for treating recurrent Clostridioides difficile infection, with donor-derived 'next generation' FMT products licensed for this condition in certain countries. Beyond FMT, other microbial therapeutic techniques-including nutritional, bacteriophage and probiotic therapies-show promise, but have not fulfilled their high expectations yet. Gut microbiome research is now well-established and shows significant translational potential; the future focus will be translational work to drive its utility in clinical diagnostics, prognostics and therapeutics.
引用
- Alexander JL, Mullish BH, Thomas L, et al. Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology. Gut. 2026. PMID: 42230119. doi:10.1136/gutjnl-2026-338252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。